These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 34464401

  • 1. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A, Mohammed R, Atnafu S, Medhin G, Hailu A.
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
    [Abstract] [Full Text] [Related]

  • 2. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R, Musa AM, Njoroge S, Omollo R, Alves F, Hailu A, Khalil EA, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M.
    Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
    [Abstract] [Full Text] [Related]

  • 3. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
    Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M.
    PLoS Negl Trop Dis; 2012 Mar; 6(6):e1674. PubMed ID: 22724029
    [Abstract] [Full Text] [Related]

  • 4. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R.
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [Abstract] [Full Text] [Related]

  • 5. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN.
    Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
    [Abstract] [Full Text] [Related]

  • 6. Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
    Mengstie TA, Endale HT, Mulaw T, Abdella AM, Mohammed R, Malik T, Dessie G.
    PLoS One; 2021 Jul; 16(10):e0257229. PubMed ID: 34597312
    [Abstract] [Full Text] [Related]

  • 7. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
    Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J, Leishmaniasis East Africa Platform (LEAP) group.
    PLoS Negl Trop Dis; 2010 Oct 26; 4(10):e709. PubMed ID: 21049059
    [Abstract] [Full Text] [Related]

  • 8. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
    Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, Muthoni Ouattara G, Egondi T, Nakanwagi P, Omollo T, Wasunna M, Verrest L, Dorlo TPC, Musa Younis B, Nour A, Taha Ahmed Elmukashfi E, Ismail Omer Haroun A, Khalil EAG, Njenga S, Fikre H, Mekonnen T, Mersha D, Sisay K, Sagaki P, Alvar J, Solomos A, Alves F.
    Clin Infect Dis; 2023 Feb 08; 76(3):e1177-e1185. PubMed ID: 36164254
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.
    PLoS Negl Trop Dis; 2017 May 08; 11(5):e0005635. PubMed ID: 28558062
    [Abstract] [Full Text] [Related]

  • 10. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA.
    Infect Dis Poverty; 2018 Oct 19; 7(1):108. PubMed ID: 30340519
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM, Mudawi Musa A, Monnerat S, Abdelrahim Saeed M, Awad Gasim Khalil E, Elbashir Ahmed A, Ahmed Ali M, Noureldin A, Muthoni Ouattara G, Nyakaya GM, Teshome S, Omollo T, Ochieng M, Egondi T, Mmbone M, Chu WY, Dorlo TPC, Zijlstra EE, Wasunna M, Alvar J, Alves F.
    PLoS Negl Trop Dis; 2023 Nov 19; 17(11):e0011780. PubMed ID: 37988402
    [Abstract] [Full Text] [Related]

  • 12. Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010).
    Uranw S, Ostyn B, Rijal A, Devkota S, Khanal B, Menten J, Boelaert M, Rijal S.
    PLoS Negl Trop Dis; 2011 Dec 19; 5(12):e1433. PubMed ID: 22206030
    [Abstract] [Full Text] [Related]

  • 13. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
    Mondal D, Kumar A, Sharma A, Ahmed MM, Hasnain MG, Alim A, Huda MM, Rahman R, Alvar J, Ahmed BN, Haque R.
    PLoS Negl Trop Dis; 2019 Aug 19; 13(8):e0007653. PubMed ID: 31415565
    [Abstract] [Full Text] [Related]

  • 14. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS, Kumar A, Hossain AFMA, Mahshin M, Sharma A, Hossain MA, Sharma V, Haque R, Shamsuzzaman AKM, Maruf S, Ghosh P, Ahuja V, Mondal D.
    Infect Dis Poverty; 2018 Aug 13; 7(1):80. PubMed ID: 30099967
    [Abstract] [Full Text] [Related]

  • 15. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.
    N Engl J Med; 2007 Jun 21; 356(25):2571-81. PubMed ID: 17582067
    [Abstract] [Full Text] [Related]

  • 16. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis.
    Ramesh V, Kumar J, Kumar D, Salotra P.
    Indian J Dermatol Venereol Leprol; 2010 Jun 21; 76(2):138-44. PubMed ID: 20228542
    [Abstract] [Full Text] [Related]

  • 17. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
    Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J.
    PLoS Negl Trop Dis; 2014 May 21; 8(5):e2875. PubMed ID: 24854196
    [Abstract] [Full Text] [Related]

  • 18. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.
    Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NK, Akhoury S, Jha S.
    BMJ; 1998 Apr 18; 316(7139):1200-5. PubMed ID: 9583927
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TP, Musa B, Ali MH, Elamin MY, Kirigi G, Juma R, Kip AE, Schoone GJ, Hailu A, Olobo J, Ellis S, Kimutai R, Wells S, Khalil EA, Strub Wourgaft N, Alves F, Musa A.
    PLoS Negl Trop Dis; 2016 Sep 18; 10(9):e0004880. PubMed ID: 27627654
    [Abstract] [Full Text] [Related]

  • 20. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.
    Clin Infect Dis; 2011 Dec 18; 53(12):e152-8. PubMed ID: 22016502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.